How were Tocagen's earnings last quarter?

Tocagen Inc (NASDAQ:TOCA) released its quarterly earnings data on Thursday, April, 23rd. The company reported ($0.43) earnings per share for the quarter, beating the consensus estimate of ($0.44) by $0.01. Tocagen had a negative trailing twelve-month return on equity of 327.74% and a negative net margin of 176,433.34%.

What other stocks do shareholders of Tocagen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tocagen investors own include Selecta Biosciences (SELB) , Inovio Pharmaceuticals (INO) , VBI Vaccines (VBIV) , SCYNEXIS (SCYX) , Catalyst Pharmaceuticals (CPRX) , T2 Biosystems (TTOO) , Amarin (AMRN) , Novavax (NVAX) , OPKO Health (OPK) and Amicus Therapeutics (FOLD) .

When did Tocagen IPO?

Tocagen (TOCA) raised $80 million in an initial public offering (IPO) on Thursday, April 13th 2017. The company issued 7,300,000 shares at a price of $10.00-$12.00 per share. Leerink Partners, Evercore ISI and Stifel acted as the underwriters for the IPO.

NASDAQ:TOCA

Tocagen (TOCA) Stock Price, News & Analysis

→ AI “wealth window” is closing soon! (From Paradigm Press) (Ad)

Free TOCA Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $0.73
▼
$0.78
50-Day Range: $1.26
▼
$41.03
52-Week Range: $0.42
▼
$6.77

Volume: 57,260 shs
Average Volume: 1.47 million shs
Market Capitalization: $17.70 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Competitors Social Media

Get Tocagen alerts:

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About Tocagen Stock (NASDAQ:TOCA)

Tocagen Inc., a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells. The company's lead product candidate is Toca 511 & Toca FC that is under Phase III clinical trial for recurrent high-grade glioma. It is also developing Toca 511 & Toca FC in a Phase Ib clinical trial for intravenous treatment of advanced cancers. In addition, the company is developing other RRVs to deliver genes to cancer cells against validated immunotherapy targets. The company has a license agreement with ApolloBio to develop and commercialize Toca 511 & Toca FC; and a collaboration agreement with NRG Oncology to develop a clinical trial utilizing Toca 511 & Toca FC for the treatment of patients with newly diagnosed glioblastoma. Tocagen Inc. was founded in 2007 and is based in San Diego, California.

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

TOCA Stock News Headlines

December 11, 2023 | markets.businessinsider.com

RiskOn International And 3 Other Stocks Under $2 Insiders Are Buying

November 2, 2023 | finance.yahoo.com

ProfoundBio Readies for Next Phase of Growth with Management Team Additions and Advisory Board Appointment

April 17, 2024 | Paradigm Press (Ad)

AI “wealth window” is closing soon!

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

February 28, 2023 | marketwatch.com

Anaplastic Oligoastrocytoma Market Industry Analysis, Estimates Size and Projections by 2029

February 27, 2023 | marketwatch.com

Companion Diagnostics Market Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2029

September 28, 2022 | marketwatch.com

Companion Diagnostics Market to show impressive growth of 11.04% CAGR during the period 2022-2027 | 102 Report Pages

April 16, 2022 | streetinsider.com

Form DEF 14A Mirati Therapeutics, For: May 12 - StreetInsider.com

March 31, 2022 | marketscreener.com

FORTE BIOSCIENCES, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K) - Marketscreener.com

April 17, 2024 | Paradigm Press (Ad)

AI “wealth window” is closing soon!

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

March 30, 2022 | newsweek.com

What Is Glioblastoma? Aggressive Cancer Linked to Death of Tom Parker - Newsweek

December 22, 2021 | seekingalpha.com

Week In Review: BeiGene Completes $3.5 Billion IPO On Shanghai STAR Board - Seeking Alpha

December 16, 2021 | finance.yahoo.com

Denovo Biopharma LLC Announces Breakthrough Discovery of a Novel Genetic Biomarker for DB107 for a Gene Therapy-Based Medicine - Yahoo Finance

September 20, 2021 | washingtonpost.com

Chasing Cancer with Meg Kinnard - The Washington Post

August 16, 2021 | marketscreener.com

FORTE BIOSCIENCES, INC. : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q) - marketscreener.com

See More Headlines

Receive TOCA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tocagen and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 4/23/2020
Today: 4/17/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical Preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:TOCA
CUSIP: N/A
CIK: 1419041
Web: www.tocagen.com
Phone: 858-412-8400
Fax: N/A
Employees: 77
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($2.69)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-63,520,000.00
Net Margins: -176,433.34%
Pretax Margin: N/A
Return on Equity: -327.74%
Return on Assets: -111.87%

Debt

Debt-to-Equity Ratio: 1.88
Current Ratio: 1.15
Quick Ratio: 1.15

Sales & Book Value

Annual Sales: $40,000.00
Price / Sales: 438.67
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.45 per share
Price / Book: 1.63

Miscellaneous

Outstanding Shares: 23,919,000
Free Float: N/A
Market Cap: $17.55 million
Optionable: Not Optionable
Beta: 0.01

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

Mr. Martin J. Duvall (Age 57)
CEO & Director
Mr. Thomas E. Darcy (Age 68)
Co-Founder & Director
Dr. Douglas J. Jolly (Age 71)
Co-Founder and Exec. VP of Research & Pharmaceutical Devel.
Mr. Mark G. Foletta C.P.A. (Age 58)
CPA, Exec. VP & CFO
Dr. Harry E. Gruber (Age 66)
Founder, Adviser & Director

Key Competitors

View All Competitors

TOCA Stock Analysis - Frequently Asked Questions

How were Tocagen's earnings last quarter?: Tocagen Inc (NASDAQ:TOCA) released its quarterly earnings data on Thursday, April, 23rd. The company reported ($0.43) earnings per share for the quarter, beating the consensus estimate of ($0.44) by $0.01. Tocagen had a negative trailing twelve-month return on equity of 327.74% and a negative net margin of 176,433.34%.
What other stocks do shareholders of Tocagen own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Tocagen investors own include Selecta Biosciences (SELB), Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), SCYNEXIS (SCYX), Catalyst Pharmaceuticals (CPRX), T2 Biosystems (TTOO), Amarin (AMRN), Novavax (NVAX), OPKO Health (OPK) and Amicus Therapeutics (FOLD).
When did Tocagen IPO?: Tocagen (TOCA) raised $80 million in an initial public offering (IPO) on Thursday, April 13th 2017. The company issued 7,300,000 shares at a price of $10.00-$12.00 per share. Leerink Partners, Evercore ISI and Stifel acted as the underwriters for the IPO.

This page (NASDAQ:TOCA) was last updated on 4/17/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Tocagen (TOCA) Stock Price, News & Analysis

About Tocagen Stock (NASDAQ:TOCA)

TOCA Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

TOCA Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info